Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The investigators designed this study to evaluate the efficiency and the acute toxicities of
recombinant human endostatin (endostar) combined with chemotherapy in the metastatic
nasopharyngeal carcinoma (NPC).
Phase:
Phase 3
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Collaborators:
Second Affiliated Hospital, School of Medicine, Zhejiang University Sir Run Run Shaw Hospital Zhejiang University